WO2004108695A1 - 抗リーシュマニア剤 - Google Patents
抗リーシュマニア剤 Download PDFInfo
- Publication number
- WO2004108695A1 WO2004108695A1 PCT/JP2004/006315 JP2004006315W WO2004108695A1 WO 2004108695 A1 WO2004108695 A1 WO 2004108695A1 JP 2004006315 W JP2004006315 W JP 2004006315W WO 2004108695 A1 WO2004108695 A1 WO 2004108695A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- unsubstituted
- methyl
- substituted
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Definitions
- the present invention relates to an anti-leishmanial agent comprising a specific compound useful for the prevention or treatment of leishmaniasis as an active ingredient.
- the present invention relates to an antimalarial agent containing a colorant compound as an active ingredient.
- Leishmaniasis is a tropical parasite infection that occurs when a parasite of the genus Leishmania parasitizes macrophages of humans and other hosts, and is transmitted mainly by sand flies that live in the desert. I do. It is designated as one of the six major tropical diseases designated by the WHO, and accounts for about 350 million patients worldwide (approximately 1.2 million people a year), mainly in Africa, the Middle East, Latin America, and Asia. Everybody is at risk of infection. Many of these people live in developing countries, and it is difficult to purchase rare and expensive drugs.
- Leishmaniasis is broadly classified into three types: cutaneous leishmaniasis (Oriental ulcer), cutaneous mucosa leishmaniasis, and visceral leishmaniasis (Kala Azar).
- Cala Azar a visceral leishmaniasis, is caused by three infections in the L. eishmania donovani group.
- cutaneous and mucosal leishmaniasis oriental aneurysms are distributed along the Mediterranean coast, Africa and the Middle and Near East.
- Three types of infections of the tropical leishmania (L. tropica) group cause ulcers on the skin due to infection.
- remote relocation ⁇ Creates a generalized lesion like a leprosy nodule.
- Brazilian New Zealand L. (B.
- braziliensis causes ulcers in the nose and oral mucosa from the initial skin lesions and deforms the same area
- L. mexicana group M. Creates lesions on the skin that are slightly different from oriental aneurysms. These various leishmaniases carry the risk of being extremely fatal if not treated sufficiently.
- the protozoan parasites are rich in diversity, and from an immunological point of view, there is a difference in antigenicity in different regions even for similar pathologies, making vaccine development difficult and necessity for chemotherapy. Is high.
- antifungal antibiotic amphotericin B amphotericin B
- Antibiotics are used intravenously secondary to fungal infections and mucocutaneous leishmaniasis, but their efficacy is less than pentavalent antimony. They are also expensive and various side effects have been reported.
- an antiprotozoal drug containing a germacran and a guaian-type sesquiterpenoid compound extracted and purified from an Asteraceae plant (Elephant alphabet mollis HBK) (see, for example, No. 2,636,695), and a therapeutic agent for leishmaniasis containing a darcoviranose derivative as an active ingredient (see, for example, JP-A-11-106394). reference. )
- an antiprotozoal drug containing a germacran and a guaian-type sesquiterpenoid compound extracted and purified from an Asteraceae plant (Elephant alphabet mollis HBK)
- a therapeutic agent for leishmaniasis containing a darcoviranose derivative as an active ingredient see, for example, JP-A-11-106394.
- JP-A-11-106394 JP-A-11-106394
- An object of the present invention is to provide a novel anti-risk drug which has few side effects, has a high cell growth inhibitory action against R. plasmodium, can be easily produced, and can be supplied at low cost. That is.
- the present inventors have proposed an anti-leishmanial agent having excellent efficacy against various types of Leishmaniasis caused by Leishmania parasites and having few side effects, a conjugated system and a heterocyclic ring containing a nitrogen atom, a nitrogen atom and a sulfur atom.
- a conjugated system and a heterocyclic ring containing a nitrogen atom, a nitrogen atom and a sulfur atom.
- Compounds in which a heterocyclic ring containing an atom is bonded to a carbon chain containing an ethylene group have been found to be useful, and various compounds having different substituents in a specific mouth danine nucleus (4-oxothiazolidine ring) have been found to be useful.
- the present invention provides a compound represented by the formula (I) (a):
- R i is an unsubstituted or substituted alkyl group having 1 to 8 carbon atoms, an unsubstituted or substituted aryl group having 6 to 8 carbon atoms, or an unsubstituted or substituted group Represents a heterocyclic group
- R 2 is a hydrogen atom, an unsubstituted or substituted alkyl group having 1 to 8 carbon atoms, an unsubstituted or substituted aryl group having 6 to 8 carbon atoms, or unsubstituted Represents a substituted or substituted heterocyclic group
- n represents an integer of 0, 1 or 2
- a and B independently represent an unsubstituted or substituted 5- to 8-membered heterocyclic group.
- An anti-leishmanial agent (Claim 5) characterized by comprising a compound represented by the formula (III) as an active ingredient, or a compound represented by the formula (II):
- R i is an unsubstituted or substituted alkyl group having 1 to 8 carbon atoms, an unsubstituted or substituted aryl group having 6 to 8 carbon atoms, or an unsubstituted or substituted group Represents a heterocyclic group
- R 2 and R 3 are independently a hydrogen atom, an unsubstituted or substituted alkyl group having 1 to 8 carbon atoms, an unsubstituted or substituted carbon atom having 6 to 8 carbon atoms.
- A represents a group of atoms necessary to form a ring, a represents a conjugated system, and Q represents a pharmaceutically acceptable anion. 6.
- oral dasocyanin color compound represented by the general formula (III) is a compound of the formula (I) (a) to (d) or the formula (IV) (a) to (m) 7.
- FIG. 1 is a photograph showing the anti-leishmania activity at each concentration of the active ingredient of the anti-leishmania agent of the present invention.
- FIG. 2 is a photograph showing the anti-leishmanial activity at each concentration of the active ingredient of the anti-leishmania agent of the present invention.
- FIG. 3 is a photograph showing the anti-Leishmania activity at each concentration of the active ingredient of the anti-Leishmania agent of the present invention.
- FIG. 4 is a photograph showing the anti-leishmanial activity at each concentration of the active ingredient of the agent of the present invention.
- the anti-leishmania agent of the present invention has a general formula ( ⁇ ): wherein Ri is an unsubstituted or substituted alkyl group having 1 to 8 carbon atoms, and an unsubstituted or substituted carbon group. Represents an aryl group having 6 to 8 atoms or an unsubstituted or substituted heterocyclic group, and R 2 is a hydrogen atom, an unsubstituted or substituted alkyl group having 1 to 8 carbon atoms, unsubstituted Or a substituted aryl group having 6 to 8 carbon atoms, or an unsubstituted or substituted heterocyclic group; n represents an integer of 0, 1 or 2; and A and B independently represent A represents a group of atoms necessary for forming a substituted or substituted 5- to 8-membered heterocycle, a represents a conjugated system, and Q represents a pharmaceutically acceptable dione.
- the compound represented by the general formula (II) as the alkyl group having 1 to 8 carbon atoms represented by R i or R 2, not only a straight chain but also a branched one may be used.
- the aryl groups of formulas 6 to 8 include phenyl, o-tolyl, m-tolyl, p-tolyl, 2,4-xyl, 3,5-xyl, benzyl, phenethyl, and phenyl.
- An example is a monomethylbenzyl group.
- Examples of the substituent bonded to the alkyl group having 1 to 8 carbon atoms or the aryl group having 6 to 8 carbon atoms represented by R i or R 2 include a halogen atom, a hydroxyl group, an oxo group, an alkyl group, and an alkyl group.
- Examples thereof include a benzyl group, an alkynyl group, an alkoxy group, an alkoxycarbonyl group, a carboxyl group, an alkylcarbonyl group, an arylcarbonyl group, an aryl group, an aralkyl group, and an amino group.
- heterocyclic group represented by R i or R 2 examples include pyrrolidine, pyrrol, pyrazole, imidazole, thiazole, isothiazol, 2-thiazoline, thiazolidine, furan, tetrahydrofuran, and 1,3 — 5-membered heterocyclic groups such as dioxolane, thiophene and tetrahydrothiophene, pyridine, piperidine, pyridazine, pyrimidine, virazine, piperazine, 2H-1,4-triazine, 4H-1,4-triazine And 6H-heterocyclic groups such as, 4H-1,4-oxazine, 2H-pyran, 4H-pyran, tetrahydrodopyran, 1,4-dioxane and the like.
- the same substituent as the above-described substituent in the alkyl group having 1 to 8 carbon atoms or the aryl group having 6 to 8 carbon atoms is preferable.
- an ortho-fused ring which is condensed with a heterocycle to form an ortho-fused ring may be used.
- Specific examples of the ortho-fused ring formed with the heterocycle include indazole, benzimidazole, benzothiazole, and benzozo. Oxazole, 1,2 monobenzoisoxazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, phthalazine, 1,,
- heterocycles include pyrrole, pyrazole, imidazole, 2-pyrazoline, 1H-1,2,3-triazole, and 1H-1,2,4-triazole.
- Examples of the substituent bonded to the heterocyclic ring formed together with the atom group represented by A include the same substituents as those described above for R 1 and R 2.
- the ortho-condensed ring which may be condensed to form an ortho-condensed ring may be, for example, an indole, indazole, benzimidazole, benzothiazol, benzoxazole, or the like. Examples thereof include 1,2-benzoisoxazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, phthalazine, and 1,8-naphthyridine.
- the heterocyclic ring formed together with B which represents an atom group necessary to form a 5- to 8-membered heterocyclic ring, has a sulfur atom and a nitrogen atom arranged at the 1,3-positions. Any of these may be used, and specifically, a 6-membered heterocyclic ring such as thiazolidine, perhydro-1,3-thiazine, tetrahydro-1,3-thiazine, or perhydro-1,3- Thiazepine, dihydro-1,3-thiazepine, tetrahydro-1,3-thia 06315
- Examples thereof include 7-membered heterocycles such as zepine and 8-membered heterocycles such as perhydro-1,3-thiazosin, dihydro-1,3-thiazosin, and tetrahydro-1,3-thiazosin.
- the ortho-fused ring formed with the heterocyclic ring may be, for example, benzothiazoline, monohydro-1,3-benzo [e] thiazine, Examples thereof include perhydro-1,3-benzo [[] thiazepine and perhydro-1,3-benzo [g] thiazosin.
- the heterocyclic ring formed together with B which represents an atom group necessary for forming a 5- to 8-membered heterocyclic ring in the above general formula (II), is preferably thiazolidine, and more preferably an oxo group at the 4-position. Having 4 oxothiazolidine rings.
- the compound having a 4-oxothiazolidine ring is more preferably an oral dasocyanine dye compound represented by the general formula (II).
- Ri is an unsubstituted or substituted alkyl group having 1 to 8 carbon atoms, an unsubstituted or substituted aryl group having 6 to 8 carbon atoms, or unsubstituted or substituted R 2 and R 3 independently represent a hydrogen atom, an unsubstituted or substituted alkyl group having 1 to 8 carbon atoms, an unsubstituted or substituted carbon atom Represents an aryl group having 6 to 8 carbon atoms, or an unsubstituted or substituted heterocyclic group; an alkyl group having 1 to 8 carbon atoms represented by R 1 R 2 and R 3 ; Examples of the aryl group, the heterocyclic group, and the substituents of the alkyl group, the aryl group, and the heterocyclic group are the same as those represented by Ri and R 2 in the general formula (II).
- the heterocyclic ring formed together with C which represents an atomic group necessary to form an unsubstituted or substituted 5- to 8-membered heterocyclic ring, specifically includes pyrrole, pyrazole, Imidazole, 2-pyrazolin, virazolidine, 1H-1,2,3-triazole, 1H-1,2,4-triazole, 4H-1,2,4-triazole, thiazole, isothiazole, 2- Thiazoline, thiazolidine, oxazole, isoxazole, 1,2,5-oxaziazol, pyridine, piperidine, piperazine, pyridazine, pyrimidine, pyrazine, 2H-1, 3-thiazine, 6H-1,3 —Examples of thiazine, 2H—1,4-monothiazine, 4H—1,
- Examples of the substituent bonded to the heterocyclic ring formed together with the group of atoms represented by C include the same substituents as those described above for R i, R 2 and R 3.
- the ortho-condensed ring which is formed by condensing with a heterocyclic ring to form an ortho-condensed ring may be, for example, indole, indolin, isoindole, isoindolin, indazole, or the like.
- Q represents a pharmaceutically acceptable anion, and any compound may be used as long as it is a pharmaceutically acceptable anion.
- Specific examples of the halogen ion include a chlorine ion, a bromine ion, an iodine ion, and the like.
- As the acid ion methanesulfonic acid
- the sulfamate ion include hexosulfamate ion, and other sulfate ions such as methyl sulfate ion and ethyl sulfate ion, hydrogen sulfate ion, borate ion, and alkyl.
- dialkyl phosphate ions carboxylate ions, carbonate ions and the like.
- Preferred specific examples of the pharmaceutically acceptable anion include chloride ion, bromide ion, iodine ion, acetate ion, propionate ion, valerate ion, quenate ion, maleate ion, fumarate ion, lactate ion, Examples thereof include succinate ion, tartaric acid ion, benzoate ion, methanesulfonic acid ion, ethanesulfonic acid ion, p-toluenesulfonic acid ion, and hydroxide ion.
- the method for producing the oral dasocyanin dye compound represented by the formula (IV) is not particularly limited, and can be produced by a known method. For example, it can be synthesized by the method described in Journal of Medicinal Chemistry (Vol. 45, pp. 995-998, 2000).
- A) a process of suspending a mixture of a thiobenzothiazol derivative, an alkyl sulfonate or the like, and 2-thioxo-4-thiazolidinone in a solvent and reacting in the presence of an amine or the like to bond the two thiazolidine derivatives; 2) Suspending the obtained compound in methyl sulfonate or the like and a solvent and heating to obtain a conjugate acid; 3) heating and reacting the conjugate acid with a pyridinium compound or the like in the presence of an amine or the like.
- an oral dasocyanin dye compound represented by the general formula (III) can be obtained.
- a combinatorial method for obtaining a variety of compound collections can also be used.
- m types of nitrogen-containing heterocyclic compounds and n types of rhodanine ring compounds are separated by mx n number of reaction units provided with a filtering means.
- a solvent such as acetonitrile
- the reaction was carried out in different combinations to remove the liquid phase, the resulting mX n merocyanine dye compounds were thiomethylated, and then r specific nitrogen-containing heterocyclic compounds.
- the reaction may be performed in the presence of a solvent such as acetonitrile so as to obtain a different combination to obtain mXnXr-type mouth dacocyanin dye compounds.
- the daily dose varies depending on the patient's condition, weight, age, sex, etc. and cannot be determined unconditionally, but the daily dose of the compound of the present invention is generally 0.1 to 100 mg, preferably 1 to 100 mg per adult per day. Preferably, 600 mg is administered.
- the anti-leishmanial agent of the present invention has excellent anti-leishmanial activity, has few side effects, and can be easily produced, so that it is versatile and excellent as an anti-leishmania agent.
- those containing an oral dasocyanin dye compound represented by the general formula (III) as an active ingredient have excellent anti-leishmanial activity, low toxicity, easy production, and anti-leishmania It is extremely useful as an agent.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0409995-8A BRPI0409995A (pt) | 2003-05-06 | 2004-04-30 | composto, e, agente anti-leishmánia |
US10/555,539 US20060252800A1 (en) | 2003-05-06 | 2004-04-30 | Anti-leishmania agent |
EP04730680A EP1623981A4 (en) | 2003-05-06 | 2004-04-30 | MEDIUM AGAINST LEISHMANIASE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003128454A JP2004331545A (ja) | 2003-05-06 | 2003-05-06 | 抗リーシュマニア剤 |
JP2003-128454 | 2003-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004108695A1 true WO2004108695A1 (ja) | 2004-12-16 |
Family
ID=33504600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/006315 WO2004108695A1 (ja) | 2003-05-06 | 2004-04-30 | 抗リーシュマニア剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060252800A1 (ja) |
EP (1) | EP1623981A4 (ja) |
JP (1) | JP2004331545A (ja) |
BR (1) | BRPI0409995A (ja) |
WO (1) | WO2004108695A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4553354B2 (ja) * | 2004-10-04 | 2010-09-29 | 正隆 井原 | 抗トリパノソーマ剤 |
JP4553355B2 (ja) * | 2004-10-04 | 2010-09-29 | 富士フイルム株式会社 | トリパノソーマ原虫寄生感染症の予防又は治療用医薬組成物 |
US20090076067A1 (en) * | 2005-06-24 | 2009-03-19 | Japan Science And Technology Agency | Pharmaceutical composition comprising azarhodacyanine compound as active ingredient |
US8038214B2 (en) | 2009-02-11 | 2011-10-18 | Cosco Management, Inc. | Harness system for juvenile vehicle seat |
WO2011046158A1 (en) | 2009-10-13 | 2011-04-21 | Hoshi University | Rhodacyanine derivative and pharmaceutical composition for treating leishmaniasis |
JP4762381B1 (ja) | 2010-10-19 | 2011-08-31 | 学校法人青山学院 | 抗リーシュマニア化合物及び抗リーシュマニア薬 |
WO2012053232A1 (ja) | 2010-10-19 | 2012-04-26 | 学校法人青山学院 | 抗リーシュマニア化合物及び抗リーシュマニア薬 |
US9642843B2 (en) | 2013-02-27 | 2017-05-09 | The Regents Of The University Of Michigan | Pharmaceutical compounds and use of same in cancer and tauopathies |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000191531A (ja) * | 1998-12-28 | 2000-07-11 | Fuji Photo Film Co Ltd | 抗マラリア剤 |
JP2003034641A (ja) * | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | ロダシアニン系色素化合物を含有する抗マラリア剤 |
JP2003034640A (ja) * | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | 四環性複素化合物を含有する抗マラリア剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT64224A (en) * | 1991-08-13 | 1993-12-28 | Dana Farber Cancer Inst Inc | Process for the production of the medical preparatives containing rodacimin applicable for treatment of cancer |
EP0772607A1 (en) * | 1994-07-21 | 1997-05-14 | Fuji Photo Film Co., Ltd. | Water-soluble methine compound and pharmaceutical composition for treatment of cancer comprising the same |
JPH0859467A (ja) * | 1994-08-18 | 1996-03-05 | Fuji Photo Film Co Ltd | 皮膚疾患治療薬 |
JP2001354564A (ja) * | 2000-06-14 | 2001-12-25 | Chugai Bunshi Igaku Kenkyusho:Kk | カチオン性ローダシアニン系色素誘導体を有効成分とする、mot−2蛋白質とp53蛋白質の相互作用阻害剤 |
JP2003034642A (ja) * | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | ロダシアニン色素化合物を含有する抗マラリア剤 |
-
2003
- 2003-05-06 JP JP2003128454A patent/JP2004331545A/ja not_active Withdrawn
-
2004
- 2004-04-30 BR BRPI0409995-8A patent/BRPI0409995A/pt not_active IP Right Cessation
- 2004-04-30 US US10/555,539 patent/US20060252800A1/en not_active Abandoned
- 2004-04-30 EP EP04730680A patent/EP1623981A4/en not_active Withdrawn
- 2004-04-30 WO PCT/JP2004/006315 patent/WO2004108695A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000191531A (ja) * | 1998-12-28 | 2000-07-11 | Fuji Photo Film Co Ltd | 抗マラリア剤 |
JP2003034641A (ja) * | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | ロダシアニン系色素化合物を含有する抗マラリア剤 |
JP2003034640A (ja) * | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | 四環性複素化合物を含有する抗マラリア剤 |
Non-Patent Citations (2)
Title |
---|
See also references of EP1623981A4 * |
TAKASU K, ET AL: "Rhodacyanine dyes as antimalarials. 1. preliminary evaluation of their activity and toxicity.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 5, 2002, pages 995 - 998, XP002957612 * |
Also Published As
Publication number | Publication date |
---|---|
EP1623981A4 (en) | 2008-07-23 |
EP1623981A1 (en) | 2006-02-08 |
BRPI0409995A (pt) | 2006-05-09 |
JP2004331545A (ja) | 2004-11-25 |
US20060252800A1 (en) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI309648B (en) | Novel chemical compounds | |
JP4792025B2 (ja) | 5−ヒドロキシインドール−3−カルボン酸エステル類誘導体およびその用途 | |
US6545009B1 (en) | Retinoid-related receptor function regulating agent | |
KR100313649B1 (ko) | 신경계질환치료제로서유용한1,4-벤조티아제핀,이의제조방법및이를포함하는약제학적조성물 | |
US20050096363A1 (en) | Activator of peroxisome proliferator-activated receptor delta | |
PT1689726E (pt) | Derivados de 5-(benz-(z)-ilideno)-tiazolidin-4-ona como agentes imunossupressores | |
NZ563866A (en) | Thiazole compounds and methods of use | |
WO1997022595A1 (fr) | Derives arylethenesulfonamide et composition de medicaments renfermant ces derives | |
US20040198768A1 (en) | Method for inhibiting 5-lipoxygenase using a benzoxazole derivative or an analogue thereof | |
NO873650L (no) | Dihydropyridinderivater. | |
WO2004108695A1 (ja) | 抗リーシュマニア剤 | |
NO763922L (ja) | ||
RU2137770C1 (ru) | Производные хинолина | |
CZ303139B6 (cs) | 2-(substituovaný amino)-benzoxazolsulfonamidový derivát, farmaceutická kompozice s jeho obsahem a zpusob in vitro inhibice retrovirové replikace | |
JPH03106875A (ja) | 1―(3―ピリジルメチル)フタラジン誘導体 | |
KR20080003924A (ko) | 염기성 질소를 갖지 않는 신규 티아졸리디논, 그의 제법,및 약제로서의 그의 용도 | |
JP2726999B2 (ja) | イミダゾ[2,1−b]ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤 | |
PL171273B1 (pl) | Sposób wytwarzania nowych pochodnych tiadiazynonów PL | |
JP3748935B2 (ja) | オキシインドール誘導体 | |
JPH01149792A (ja) | 6‐クロロ‐4‐ヒドロキシ‐2‐メチル‐N‐(2‐ピリジル)‐2H‐チエノ〔2,3‐e〕‐1,2‐チアジン‐3‐カルボキサミド‐1,1‐ジオキシドのエノールエーテル、その製造方法および用途 | |
JP2008538756A (ja) | 塩基性窒素を有さない新規チアゾリジノン類、それらの生成及び医薬剤としての使用 | |
WO2003007948A1 (fr) | Antipaludique contenant un compose de rhodacyanine | |
EP0589908A1 (de) | Aminoalkylsubstituierte thiazolin-2-one, ihre herstellung und verwendung | |
GB1569238A (en) | 2,5-dihdro-1,2-thiazino(5,6-b)indol-3-carboxamide-1,1-dioxide derivatives | |
HUT65938A (en) | Process for the production of 4-cynnolinyl- and 4-naphthyridinyl-dihydropyridines and pharmaceutical compositions containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004730680 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5187/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006252800 Country of ref document: US Ref document number: 10555539 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004730680 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0409995 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10555539 Country of ref document: US |